{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000780","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.595318+00:00","generated_at":"2026-06-07T02:01:21.303166+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cardiff Oncology presents onvansertib data: 73% DCR in 2L KRAS-mut mCRC; FDA Type C meeting supports accelerated path","bullets":["73% disease control rate in 2L KRAS-mutated mCRC; median overall survival 15 months vs ~8 months historical.","FDA Type C meeting (June 2023) agreed on mCRC development plan supporting potential accelerated approval.","Topline data from 1st-line RAS-mutated mCRC trial expected mid-2024.","Cash runway extends into 2025; collaboration with Pfizer under Pfizer Ignite program.","Preclinical data show onvansertib + bevacizumab reduces tumor size and vascularization in KRAS G12V model."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000780","json":"https://secwatch.observer/filing/0001628280-24-000780.json","markdown":"https://secwatch.observer/filing/0001628280-24-000780.md","text":"https://secwatch.observer/filing/0001628280-24-000780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024000780/0001628280-24-000780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024000780/crdf-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:01:21.303166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}